Important Notice
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial condition, and future development plans, investors should carefully read the full annual report on the designated media.
All directors attended the board meeting that reviewed this report.
The audit opinion of Zhonghui Certified Public Accountants (Special General Partnership) on the company's financial report for the year was: Standard Unqualified Opinion.
Notice of Non-Standard Audit Opinion □ Applicable Not Applicable
The company was not profitable at the time of listing and has not yet achieved profitability. □ Applicable Not Applicable
Board of Directors' review of the profit distribution proposal or capital reserve to share capital increase proposal for the reporting period ☑ Applicable Not Applicable
The profit distribution proposal reviewed and approved by the Board of Directors for the current reporting period is: Based on the total share capital on the equity distribution registration date, minus the shares in the dedicated securities account for share repurchases, the remaining shares will be used as the base. A cash dividend of 1.50 yuan (tax inclusive) per 10 shares will be distributed to all shareholders, with 0 bonus shares (tax inclusive) and 0 shares transferred from capital reserve per 10 shares.
Board of Directors' resolution on the preferred share profit distribution proposal for the reporting period □ Applicable Not Applicable
Company Basic Information
1. Company Profile
| Stock Abbreviation | Listed Stock Exchange | Stock Code |
|---|---|---|
| Minsheng Health | Shenzhen Stock Exchange | 301507 |
| Contact Person and Contact Information | Board Secretary | Securities Affairs Representative |
|---|---|---|
| [blank] | [blank] | [blank] |
| Name | Office Address | Fax | Telephone | |
|---|---|---|---|---|
| Wenzhu Bao | No. 658, Bin'an Road, Binjiang District, Hangzhou | 0571-88846691 | 0571-88211731 | msjk@mspharm.com |
| Weixia Bao | No. 658, Bin'an Road, Binjiang District, Hangzhou | 0571-88846691 | 0571-88211731 | msjk@mspharm.com |
2. Main Business and Products in the Reporting Period
(1) Industry Situation in the Reporting Period
According to the classification of national economic industries, the company's industry belongs to C27 Pharmaceutical Manufacturing. The company's main product, 21st Century Multivitamin Tablets (21), is classified as a Class B over-the-counter (OTC) drug. As an important part of the pharmaceutical industry, the OTC drug market has shown a trend of sustained and stable growth in recent years. With the improvement of people's health awareness and the strengthening of health knowledge popularization among consumers, self-medication is becoming increasingly popular, and the concept of preventing illness before it occurs is gradually forming, which will further promote the development of the OTC drug industry. At the same time, the rapid promotion of the hierarchical diagnosis and treatment system across the country has created space for the grassroots pharmaceutical market, accelerated the transformation of retail pharmacies, and brought more opportunities for the expansion of the OTC drug market.